---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-22-000026"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:32:13.306060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M

## Summary
- Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.
- Net loss $11.8M vs $8.1M prior year; operating expenses $18.2M vs $13.8M.
- Cash and equivalents $85.4M, down from $92.4M at June 30; long-term debt $52.0M.
- Gross margin 71% vs 73% due to short-term supply chain disruption, now resolved.
- Initiated distribution of DIXI Medical stereo EEG electrodes on Oct 1, 2022.

## SEC filing metadata
- accession: 0001528287-22-000026
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/npce-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-22-000026
- JSON: https://secwatch.observer/filing/0001528287-22-000026.json
- Plain text: https://secwatch.observer/filing/0001528287-22-000026.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported the quarter ending September 30, 2022 results: revenue $11.2 million, net income $11.8 million. Guidance raised.
  - Period: the quarter ending September 30, 2022
  - Revenue: $11.2 million
  - Net income: $11.8 million
  - Guidance: raised
  - Result: reported results
  source text: the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Recent Highlights • Achieved total revenue of $11.2 million for the third quarter of 2022, representing growth of 8% compared to the third quarter of 2021 and 9% compared to the second quarter of 2022 • Achieved initial implant revenue of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.